Press release
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.Download the sample report @ https://www.pharmaproff.com/request-sample/1164
Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased appetite and nausea.
In advanced renal cell carcinoma, which is a form of kidney cancer, Cabozantinib is used in those patients who have been previously treated with a type of cancer medicine called ‘vascular endothelial growth factor (VEGF) inhibitor.
Get the detailed analysis @ https://www.pharmaproff.com/report/cabozantinib
It is also used in patients who have not undergone previous treatment and whose cancer is at moderate or high risk. In hepatocellular carcinoma, which is a form of liver cancer, it is used in patients who have already been treated with the cancer medicine such as Sorafenib. It is currently marketed in Europe and the U.S.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1164
This report provides details of the drug and the API manufacturers across the 7 major markets which includes U.S, EU5, and Japan. It includes the overview, mechanism, regulatory milestones, strategic developments, the historical and forecasted sales. The pipeline analysis of the drug by phase which would include the product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cabozantinib- API Insight, 2018 here
News-ID: 1711171 • Views: …
More Releases for VEGF
Anti-VEGF Therapeutics Market In-Deep Research and Forecast Report
The revenue of the anti-VEGF therapeutics market will increase from $12,178.0 million in 2021 at a compound annual growth rate of 1.4% from 2021 to 2030, to touch $13,812.6 million by 2030. The development of the industry is mainly driven by the approvals of the FDA to a number of drug candidates, accompanied by R&D activities.
Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/anti-vascular-endothelial-growth-factor-therapeutics-market/report-sample
Eylea held the largest share in the…
(Post-pandemic Era) - VEGF Antibody Market Future Developments and Industry Size …
According to Research study, over the next 5 years the (Post-pandemic Era) - VEGF Antibody market will register a xx% CAGR in terms of revenue, the global market size will reach xx Million USD by 2026, from xx Million USD in 2020. In particular, it should be noted that the impact of the epidemic has accelerated the trend of localization, regionalization and decentralization of the global industrial chain and supply…
Global VEGF/VEGFR Inhibitor Drugs Industry Research Analysis by 2020- 2025
This report also researches and evaluates the impact of Covid-19 outbreak on the VEGF/VEGFR Inhibitor Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on VEGF/VEGFR Inhibitor Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
GLOBAL INFO RESEARCH has lately published a new report titled, *Global and Japan VEGF/VEGFR Inhibitor Drugs Market 2020 by Company, Type and Application, Forecast to…
Vascular Endothelial Growth Factor (VEGF) Antibodies Market By 2026 Genentech, N …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,…
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Opportunity Analysis …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,…
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Report Explored in L …
Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market: Overview
Vascular endothelial growth factor is an integral part of several pathophysiological processes. This is the primary reason why it is extensively used for designing therapies to treat patients with macular degeneration and cancers. The global vascular endothelial growth factor (VEGF) antibodies is gaining momentum as it is known to be far more effective than conventional pharmaceuticals.
Currently, VEGF antibodies used for treating…
